CKPT - Checkpoint Therapeutics Inc Stock Price, Fair Value and News

$3.75+0.38 (+11.28%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CKPT Price Action

Last 7 days

2.2%

Last 30 days

11.0%

Last 90 days

55.6%

Trailing 12 Months

103.8%

CKPT RSI Chart

CKPT Valuation

Market Cap

169.1M

Price/Earnings (Trailing)

-3.64

Price/Sales (Trailing)

2.2K

Price/Free Cashflow

-5.5

CKPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CKPT Fundamentals

CKPT Revenue

Revenue (TTM)

78.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

CKPT Earnings

Earnings (TTM)

-46.5M

Earnings Growth (Yr)

-69.9%

Earnings Growth (Qtr)

-45.8%

CKPT Profitability

Return on Equity

369.09%

Return on Assets

-897.24%

Free Cashflow Yield

-18.19%

CKPT Investor Care

Shares Dilution (1Y)

184.65%

Diluted EPS (TTM)

-1.76

CKPT Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	109.0K	78.0K	0
2023	175.0K	188.0K	171.0K	103.0K
2022	252.0K	115.0K	134.0K	192.0K
2021	165.0K	278.0K	279.0K	268.0K
2020	2.3M	1.3M	1.1M	1.1M
2019	3.5M	4.4M	4.7M	1.7M
2018	1.4M	1.2M	807.0K	3.5M
2017	3.0M	2.1M	1.9M	1.7M
2016	1.1M	1.6M	2.1M	2.6M
2015	0	0	0	590.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CEO	Mr. James F. Oliviero III, C.F.A., CFA
WEBSITE	checkpointtx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	24

Checkpoint Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Checkpoint Therapeutics Inc? What does CKPT stand for in stocks?

CKPT is the stock ticker symbol of Checkpoint Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Checkpoint Therapeutics Inc (CKPT)?

As of Fri Dec 20 2024, market cap of Checkpoint Therapeutics Inc is 169.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CKPT stock?

You can check CKPT's fair value in chart for subscribers.

Is Checkpoint Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CKPT is over valued or under valued. Whether Checkpoint Therapeutics Inc is cheap or expensive depends on the assumptions which impact Checkpoint Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CKPT.

What is Checkpoint Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CKPT's PE ratio (Price to Earnings) is -3.64 and Price to Sales (PS) ratio is 2.17 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CKPT PE ratio will change depending on the future growth rate expectations of investors.